Drug Combination Details
| General Information of the Combination (ID: C71701) | |||||
|---|---|---|---|---|---|
| Name | Eugenol NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in S and G2/M phase | ||||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Eugenol interacts synergistically with 5-fluorouracil against human cervical cancer, HeLa cell lines, by blocking the cell cycle and inducing apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of phenylpropanoids with 5-fluorouracil as anti-cancer agents against human cervical cancer (HeLa) cell line. Phytomedicine. 2013 Jan 15;20(2):151-8. | |||
